Table 3.
Estimated maximum adverse effects of individual statins from Emax dose-response models*
| Statin | Muscle symptoms | Muscle disorders | Liver dysfunction | Renal insufficiency | Diabetes | Eye conditions |
|---|---|---|---|---|---|---|
| Atorvastatin | 1.35 (0.92 to 4.46) | 0.89 (0.47 to 1.67) | 2.03 (1.03 to 12.64) | 1.35 (0.61 to 12.83) | 1.18 (0.37 to 4.39) | 1.32 (0.36 to 6.10) |
| Fluvastatin | 1.10 (0.61 to 5.12) | 1.12 (0.49 to 2.79) | 1.02 (0.34 to 33.99) | No data | No data | No data |
| Lovastatin | 1.25 (0.79 to 5.00) | 0.85 (0.46 to 1.46) | 3.29 (0.95 to 40.24) | No data | 0.98 (0.14 to 5.63) | 1.09 (0.38 to 2.83) |
| Pitavastatin | 0.85 (0.43 to 2.01) | 0.94 (0.27 to 2.62) | 1.50 (0.41 to 100.85) | 0.94 (0.27 to 4.70) | 0.74 (0.19 to 3.34) | No data |
| Pravastatin | 1.18 (0.79 to 4.84) | 1.02 (0.58 to 1.76) | 1.13 (0.59 to 14.72) | 1.33 (0.60 to 4.57) | 0.95 (0.25 to 3.77) | 0.91 (0.26 to 3.33) |
| Rosuvastatin | 1.26 (0.97 to 2.82) | 0.92 (0.45 to 1.63) | 1.61 (0.75 to 16.82) | 1.39 (0.84 to 11.03) | 1.16 (0.22 to 4.33) | 1.36 (0.56 to 4.22) |
| Simvastatin | 0.83 (0.44 to 2.58) | 0.94 (0.44 to 2.06) | 1.59 (0.60 to 21.95) | 1.17 (0.48 to 5.20) | No data | No data |
Emax=asymptotic maximum drug effect.
*
The maximum odds ratio (ORmax) with 95% credible interval (CrI) in each cell is the maximum effect of each statin on the adverse event compared with non-statin controls (that is, the dose of the statin is 0), which is the natural exponential form of the estimated parameter, Emax, in each model.